These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 11249520)

  • 1. Orlistat in the treatment of obesity.
    Ballinger A
    Expert Opin Pharmacother; 2000 May; 1(4):841-7. PubMed ID: 11249520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orlistat: a review of its use in the management of obesity.
    Hvizdos KM; Markham A
    Drugs; 1999 Oct; 58(4):743-60. PubMed ID: 10551441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orlistat--a novel weight loss therapy.
    Lucas KH; Kaplan-Machlis B
    Ann Pharmacother; 2001 Mar; 35(3):314-28. PubMed ID: 11261530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
    Leung WY; Thomas GN; Chan JC; Tomlinson B
    Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N; James WP; Kopelman PG; Lean ME; Williams G
    Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orlistat.
    Wong NN; Cheng-Lai A
    Heart Dis; 2000; 2(2):174-81. PubMed ID: 11728255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orlistat: its current status as an anti-obesity drug.
    Ballinger A; Peikin SR
    Eur J Pharmacol; 2002 Apr; 440(2-3):109-17. PubMed ID: 12007529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on orlistat in the management of patients with obesity.
    Curran MP; Scott LJ
    Treat Endocrinol; 2005; 4(2):127-9. PubMed ID: 15783249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orlistat: a review of its use in the management of patients with obesity.
    Curran MP; Scott LJ
    Drugs; 2004; 64(24):2845-64. PubMed ID: 15563254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
    Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M
    Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study.
    Shirai K; Tanaka M; Fujita T; Fujii Y; Shimomasuda M; Sakai S; Samukawa Y
    Adv Ther; 2019 Jan; 36(1):217-231. PubMed ID: 30387022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orlistat: current status in clinical therapeutics.
    McClendon KS; Riche DM; Uwaifo GI
    Expert Opin Drug Saf; 2009 Nov; 8(6):727-44. PubMed ID: 19998527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological management of obesity.
    Hanif MW; Kumar S
    Expert Opin Pharmacother; 2002 Dec; 3(12):1711-8. PubMed ID: 12472368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial.
    Bloch KV; Salles GF; Muxfeldt ES; Da Rocha Nogueira A
    J Hypertens; 2003 Nov; 21(11):2159-65. PubMed ID: 14597860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
    Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
    Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit-risk assessment of orlistat in the treatment of obesity.
    Sumithran P; Proietto J
    Drug Saf; 2014 Aug; 37(8):597-608. PubMed ID: 25064699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
    Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J
    JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.